33,091 Shares in Royalty Pharma plc (NASDAQ:RPRX) Bought by Aubrey Capital Management Ltd

Aubrey Capital Management Ltd acquired a new position in shares of Royalty Pharma plc (NASDAQ:RPRX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 33,091 shares of the biopharmaceutical company’s stock, valued at approximately $926,000.

Several other large investors have also modified their holdings of RPRX. CWM LLC boosted its holdings in shares of Royalty Pharma by 75.9% during the 3rd quarter. CWM LLC now owns 4,782 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 2,064 shares during the period. Handelsbanken Fonder AB boosted its holdings in Royalty Pharma by 17.7% in the 3rd quarter. Handelsbanken Fonder AB now owns 931,636 shares of the biopharmaceutical company’s stock valued at $25,285,000 after purchasing an additional 140,300 shares during the period. Linden Thomas Advisory Services LLC bought a new stake in Royalty Pharma in the 3rd quarter valued at $782,000. Ridgewood Investments LLC boosted its holdings in Royalty Pharma by 19.8% in the 3rd quarter. Ridgewood Investments LLC now owns 25,787 shares of the biopharmaceutical company’s stock valued at $700,000 after purchasing an additional 4,267 shares during the period. Finally, Xponance Inc. boosted its holdings in Royalty Pharma by 38.8% in the 3rd quarter. Xponance Inc. now owns 18,218 shares of the biopharmaceutical company’s stock valued at $494,000 after purchasing an additional 5,090 shares during the period. 54.35% of the stock is owned by institutional investors.

Royalty Pharma Price Performance

Shares of RPRX stock traded down $0.11 during mid-day trading on Friday, reaching $28.00. The company’s stock had a trading volume of 1,748,254 shares, compared to its average volume of 2,545,847. Royalty Pharma plc has a 1-year low of $25.92 and a 1-year high of $35.76. The company has a market cap of $16.73 billion, a P/E ratio of 14.81 and a beta of 0.45. The company has a debt-to-equity ratio of 0.61, a quick ratio of 7.90 and a current ratio of 7.90. The firm’s 50-day moving average is $29.61 and its two-hundred day moving average is $28.55.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.12. Royalty Pharma had a net margin of 48.22% and a return on equity of 26.93%. The company had revenue of $736.00 million during the quarter, compared to analysts’ expectations of $702.90 million. On average, research analysts predict that Royalty Pharma plc will post 3.95 earnings per share for the current year.

Royalty Pharma Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 17th will be given a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.00%. The ex-dividend date of this dividend is Thursday, May 16th. Royalty Pharma’s dividend payout ratio (DPR) is currently 44.44%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on RPRX. The Goldman Sachs Group reduced their price target on shares of Royalty Pharma from $56.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, February 20th. JPMorgan Chase & Co. reduced their price target on shares of Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating for the company in a report on Tuesday, February 20th. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a report on Thursday, April 11th. Finally, Bank of America dropped their price objective on shares of Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a research note on Friday, April 12th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Royalty Pharma has an average rating of “Buy” and a consensus target price of $46.75.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.